Primary Hyperoxaluria Type 2
Symptoms, Doctors, Treatments, Advances & More

Primary Hyperoxaluria Type 2 Overview

Save information for later
Sign Up

Learn About Primary Hyperoxaluria Type 2

What is the definition of Primary Hyperoxaluria Type 2?
Primary hyperoxaluria type 2 is a rare condition characterized by the overproduction of a substance called oxalate (also called oxalic acid). In the kidneys, the excess oxalate combines with calcium to form calcium oxalate, a hard compound that is the main component of kidney stones. Deposits of calcium oxalate can lead to kidney damage, kidney failure, and injury to other organs. Primary hyperoxaluria type 2 is caused by the shortage (deficiency) of an enzyme called glyoxylate reductase/hydroxypyruvate reductase (GRHPR) that normally prevents the buildup of oxalate. This enzyme shortage is caused by genetic changes in the GRHPR gene. Primary hyperoxaluria type 2 is inherited in an autosomal recessive pattern.
What are the alternative names for Primary Hyperoxaluria Type 2?
  • Primary hyperoxaluria type 2
  • D-glycerate dehydrogenase deficiency
  • Glyceric aciduria
  • Glyoxylate reductase/hydroxypyruvate reductase deficiency
  • HP2
  • Oxalosis 2
Who are the top Primary Hyperoxaluria Type 2 Local Doctors?
Elite in Primary Hyperoxaluria Type 2
Dr. Dawn Milliner
Nephrology
Elite in Primary Hyperoxaluria Type 2
Dr. Dawn Milliner
Nephrology

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
507-284-2511
Languages Spoken:
English

Dawn Milliner is a Nephrologist practicing medicine in Virginia Beach, Virginia. Dr. Milliner is rated as an Elite provider by MediFind in the treatment of Primary Hyperoxaluria Type 2. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Primary Hyperoxaluria, Primary Hyperoxaluria Type 2, Nephrocalcinosis, Kidney Transplant, and Endoscopy.

Elite in Primary Hyperoxaluria Type 2
Dr. John Lieske
Nephrology
Elite in Primary Hyperoxaluria Type 2
Dr. John Lieske
Nephrology

Mayo Clinic-Rochester

200 1st St SW, 
Rochester, MN 
507-284-9991
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Lieske is a Nephrologist practicing medicine in Rochester, Minnesota. Dr. Lieske is rated as an Elite provider by MediFind in the treatment of Primary Hyperoxaluria Type 2. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Kidney Stones, Nephrocalcinosis, Primary Hyperoxaluria, Kidney Transplant, and Lithotripsy.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Primary Hyperoxaluria Type 2
Dr. Krishna Komanduri
Internal Medicine | Nephrology
Experienced in Primary Hyperoxaluria Type 2
Dr. Krishna Komanduri
Internal Medicine | Nephrology

Kidney Care Specialists LLC - Nephrology Associates Division

2223 E High St, 
Pottstown, PA 
610-649-1175
Languages Spoken:
English
See accepted insurances
Offers Telehealth

. Dr. Komanduri is rated as an Experienced provider by MediFind in the treatment of Primary Hyperoxaluria Type 2. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Acute Kidney Failure, Chronic Kidney Disease, Cytomegalovirus Infection, Necrosis, and Bone Graft. Dr. Komanduri is board certified in American Board Of Internal Medicine.

View All Doctors
What are the latest Primary Hyperoxaluria Type 2 Clinical Trials?
Rare Kidney Stone Consortium Biobank, Rare Diseases Clinical Research Network
Rare Kidney Stone Consortium Biobank, Rare Diseases Clinical Research Network
Enrollment Status: Recruiting
Publish Date: July 22, 2025

Summary: This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research.

Match to trials
Find the right clinical trials for you in under a minute
Get started
View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center